Pancreatic Cancer News and Research RSS Feed - Pancreatic Cancer News and Research

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

Research shows PODXL protein contributes to aggressive forms of bladder cancer

Aggressive forms of bladder cancer involve the protein PODXL - a discovery that could hold the key to improved treatment, according to researchers at Lund University, Uppsala University and KTH in Sweden. [More]
FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer. [More]
Obesity directly tied to several cancers

Obesity directly tied to several cancers

"Obesity is a major risk factor for developing cancer, roughly the equivalent of tobacco use, and both are potentially reversible. Further, obese cancer patients do worse in surgery, with radiation or on chemotherapy - worse by any measure." Karen Basen-Engquist, Ph.D., Director of MD Anderson's new Center for Energy Balance in Cancer Prevention and Survivorship and professor of Behavioral Science. [More]
Promising method to distinguish pancreatic cancer from chronic pancreatitis

Promising method to distinguish pancreatic cancer from chronic pancreatitis

Researchers at Mayo Clinic have developed a promising method to distinguish between pancreatic cancer and chronic pancreatitis - two disorders that are difficult to tell apart. A molecular marker obtained from pancreatic "juices" can identify almost all cases of pancreatic cancer, their study shows. [More]
AGA announces first AGA-Caroline Craig Augustyn and Damian Augustyn Award in Digestive Cancer

AGA announces first AGA-Caroline Craig Augustyn and Damian Augustyn Award in Digestive Cancer

The AGA Research Foundation is honored to announce the first AGA-Caroline Craig Augustyn and Damian Augustyn Award in Digestive Cancer, which will support Andrew D. Rhim, MD, from the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, as he furthers his research on the role of Zeb1 in pancreas development, regeneration and cancer progression. [More]
ElsaLys Biotech announces first round of financing from Transgene and Sofimac Partners

ElsaLys Biotech announces first round of financing from Transgene and Sofimac Partners

ElsaLys Biotech, which specializes in the development of therapeutic monoclonal antibodies, announces a first round of financing of 2.1M€ from the biopharmaceutical company Transgene and the investment fund Sofimac Partners. [More]
AGA researchers to present exciting data on GI disorders at DDW 2013

AGA researchers to present exciting data on GI disorders at DDW 2013

Clinicians, researchers and scientists from around the world will gather for Digestive Disease Week- 2013, the largest and most prestigious gastroenterology meeting, from May 18 to 21, 2013, at the Orange County Convention Center in Orlando, FL. [More]

Study underscores new paradigm in cancer therapy

In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. [More]

Researchers unravel a mystery about how pancreatic tumor cells feed themselves

In a landmark cancer study published online in Nature, researchers at NYU School of Medicine have unraveled a longstanding mystery about how pancreatic tumor cells feed themselves, opening up new therapeutic possibilities for a notoriously lethal disease with few treatment options. [More]

ScinoPharm Taiwan, Coland Holdings partner to develop generic oncological drugs for China

ScinoPharm Taiwan Ltd. and Coland Holdings Ltd. announced today that they have formed a strategic alliance to develop a series of generic oncological drugs for Mainland China. [More]
Special issue of Gastroenterology presents variety of topics related to pancreas

Special issue of Gastroenterology presents variety of topics related to pancreas

The editors of Gastroenterology, the official journal of the American Gastroenterological Association Institute, are pleased to announce the publication of this year's highly anticipated special 13th issue. [More]
Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Kinase inhibitors are molecules that block the activity of kinases. Kinases are a specific class of enzymes. They are extremely important in signal transduction processes in the human body meaning that they actually regulate most of the physiological processes that take place in the body. [More]
Findings set the stage for identifying potential new drug targets, treatment strategies for AML

Findings set the stage for identifying potential new drug targets, treatment strategies for AML

nvestigators for The Cancer Genome Atlas Research Network have detailed and broadly classified the genomic alterations that frequently underlie the development of acute myeloid leukemia, a deadly cancer of the blood and bone marrow. [More]
Details about genomic landscapes of AML and endometrial cancer revealed

Details about genomic landscapes of AML and endometrial cancer revealed

Two studies from The Cancer Genome Atlas program reveal details about the genomic landscapes of acute myeloid leukemia and endometrial cancer. [More]
Pancreatitis and diabetes drugs: an interview with Dr Sonal Singh, Johns Hopkins University School of Medicine

Pancreatitis and diabetes drugs: an interview with Dr Sonal Singh, Johns Hopkins University School of Medicine

Acute pancreatitis is an inflammation of the pancreas which leads to leakage of pancreatic enzymes. Apart from certain drugs such as GLP-1 based therapies, the most common causes of pancreatitis are Gallstones and Alcohol use. [More]
Novel approach using Listeria bacteria shows promise against metastatic pancreatic cancer

Novel approach using Listeria bacteria shows promise against metastatic pancreatic cancer

Researchers at Albert Einstein College of Medicine of Yeshiva University have developed a therapy for pancreatic cancer that uses Listeria bacteria to selectively infect tumor cells and deliver radioisotopes into them. [More]

TGen receives donation from Seena Magowitz Foundation for pancreatic cancer research

The Seena Magowitz Foundation has donated $500,000 from two charity golf tournaments dedicated to supporting pancreatic cancer research at the Translational Genomics Research Institute. [More]

University of Leicester study investigates early detection of pancreatic cancer

Pioneering research to investigate whether pancreatic cancer can be detected early through a blood test is to be spearheaded by the University of Leicester thanks to new funding provided by Hope Against Cancer. [More]
Review summarises current data on markers for pancreatic cancer

Review summarises current data on markers for pancreatic cancer

A team of researchers of the UPV/EHU together with researchers from the Hospital Clínico of Barcelona have produced a bibliographical review that summarises the data currently existing on the markers for pancreatic cancer, and have published it in the specialised journal Clinica Chimica Acta. [More]
New chemical compound offers a promising step for creating potential anti-cancer agents

New chemical compound offers a promising step for creating potential anti-cancer agents

Scientists at the Walter and Eliza Hall Institute and their collaborators have tailor-made a new chemical compound that blocks a protein that has been linked to poor responses to treatment in cancer patients. [More]